WCN24-2145 ACUTE EFFECT OF FERRIC CARBOXYMALTOSE ON OXIDATIVE STRESS IN NON-DIALYSIS CKD PATIENTS

WCN24-2145 ACUTE EFFECT OF FERRIC CARBOXYMALTOSE ON OXIDATIVE STRESS IN NON-DIALYSIS CKD PATIENTS

Saved in:

Bibliographic Details
Main Authors:	Ana Maria Mehedinti, Iuliana Andreiana, Gabriel Mircescu, Cristina Capusa
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924009938
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bone marrow macrophage iron content and sideroblast count in iron- and ESA-naïve patients with CKD-related anemia
by: Cristina Capusa, et al.
Published: (2023-12-01)

Ferric Carboxymaltose in the Treatment of Anemia in Patients with Locally Advanced Colon Cancer
by: D. O. Kornev, et al.
Published: (2025-04-01)

WCN24-1839 REAL-WORLD USEFULNESS OF KIDNEY FAILURE RISK EQUATION IN ADULTS WITH BIOPSY-PROVEN GLOMERULOPATHIES
by: Cristina Căpușă, et al.
Published: (2024-04-01)

The use of parenteral application of ferric carboxymaltose in the prevention of iron deficiency anaemia in suckling piglets
by: M Svoboda, et al.
Published: (2025-07-01)

Efficacy of Ferric Carboxymaltose in Iron Deficiency Anaemia Management in Non Dialysis Dependent Chronic Kidney Disease Patients: A Retrospective Observational Study
by: Anil Kumar Bhalla, et al.
Published: (2025-08-01)

WCN25-1805 THE EFFECT OF INTRAVENOUS FERRIC CARBOXYMALTOSE ON SERUM IFGF23 AND SERUM PHOSPHATE LEVELS IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH IRON INSUFFICIENCY: A PROSPECTIVE STUDY
by: Deepakkumar Prasad, et al.
Published: (2025-02-01)

WCN24-2168 PHENOTYPE OF CKD-BMD IN A DIALYSIS POPULATION OF MEXICO
by: Lia Daniela Luna-Navarro, et al.
Published: (2024-04-01)

Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis
by: Burhanuddin Sohail Rangwala, et al.
Published: (2024-12-01)

Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency
by: Anastasios Tsarouchas, et al.
Published: (2025-08-01)

Effect of ferric carboxymaltose in the iron deficiency anemia patients undergoing cardiac surgery: A randomized clinical trial
by: Fateme Ramezani, et al.
Published: (2024-05-01)

Potentially Life-Threatening Phosphate Diabetes Induced by Ferric Carboxymaltose Injection: A Case Report and Review of the Literature
by: Xavier Vandemergel, et al.
Published: (2014-01-01)

Hypocalcemia and Hypophosphatemia following Concurrent Denosumab Injection and Ferric Carboxymaltose Infusion in a Patient with Normal Renal Function
by: Naomi Szwarcbard, et al.
Published: (2024-01-01)

Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis
by: Ayesha Khan, et al.
Published: (2025-01-01)

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
by: Charles F. Barish, et al.
Published: (2012-01-01)

Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience
by: Nikolina Brkić, et al.
Published: (2024-01-01)

WCN24-2175 Priorities in nutrition of health professionals and population with CKD without dialysis, Chilean preliminary data
by: Francisca Peña, et al.
Published: (2024-04-01)

Retrospective Case Reports of Anemic Pregnant Women Receiving Intravenous Ferric Carboxymaltose: Experience from a Tertiary Hospital in Spain
by: Rafael Aporta Rodriguez, et al.
Published: (2016-01-01)

The Effect of Ferric Carboxymaltose on Fibroblast Growth Factor 23 (FGF23) in Children with Iron Deficiency Anemia Due to Gastrointestinal Diseases
by: Maria Ntoumpara, et al.
Published: (2024-11-01)

Comparative Impact of Intravenous Iron Sucrose and Ferric Carboxymaltose on Hypophosphatemia and Anemia Parameters in Iron Deficiency Anemia: A Retrospective Study
by: Aslan S, et al.
Published: (2025-06-01)

Influence of intravenous ferric carboxymaltose on non-invasive parameters of left ventricular myocardial work in patients with heart failure with reduced ejection fraction
by: Zh. D. Kobalava, et al.
Published: (2023-02-01)

Patient with Secondary Amyloidosis Due to Crohn’s Disease on Hemodialysis Effectively Treated with Ferric Carboxymaltose Injections: A Case Report and Literature Review
by: Masayo Ueno, et al.
Published: (2025-04-01)

Low-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial.
by: Takeshi Nagao, et al.
Published: (2025-01-01)

The Efficacy and Safety of Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Inderbir Padda, et al.
Published: (2024-12-01)

WCN25-2306 THE BURDEN OF TRAVELLING DISTANCE TO THE DIALYSIS CENTRE ON CKD PATIENTS IN INDIA
by: Deepa Usulumarty, et al.
Published: (2025-02-01)

WCN24-418 DIALYSIS FLUID MANAGEMENT – LET'S MAKE DIALYSIS GREENER
by: Jacek Zawierucha, et al.
Published: (2024-04-01)

WCN24-1157 ASSESSING THE CURRENT LANDSCAPE: UTILIZATION TRENDS OF RAAS INHIBITORS IN HYPERTENSION MANAGEMENT FOR NON-DIALYSIS DEPENDENT CKD PATIENTS AMONG PHYSICIANS
by: Sourabh Sharma, et al.
Published: (2024-04-01)

WCN24-171 DIALYSIS IN NEW OLD PATIENTS
by: Victor Frajewicki, et al.
Published: (2024-04-01)

WCN25-4121 CHANGES OF GREAT VESSELS AND CARDIAC VALVES OF CKD STAGE 5 ( BOTH DIALYSIS AND NON DIALYSIS) PATIENTS
by: Lutfa Bintey Kabir, et al.
Published: (2025-02-01)

WCN24-2596 HYPOKALEMIA AND ITS CLINICAL ASSOCIATION IN PERITONEAL DIALYSIS
by: Milagros Melissa Flores Fonseca, et al.
Published: (2024-04-01)

WCN24-1129 CKD-MBD Status in Maintenance Hemodialysis Patients in Bangladesh
by: Farnaz Nobi, et al.
Published: (2024-04-01)

REACTIVATION OF FERRIC OXIDES IN ROTARY FURNACES
by: S. L. Rovin, et al.
Published: (2011-02-01)

The Effect of Ferric Oxide on Candida albicans
by: Rima M.Y. Nasif, et al.
Published: (2025-07-01)

WCN25-2356 REAL WORLD EXPERIENCE OF HIF-PHI – DESIDUSTAT (OXEMIA®) IN DIALYSIS AND NON-DIALYSIS DEPENDENT CKD ANEMIA PATIENTS
by: Vijay Sinha, et al.
Published: (2025-02-01)

WCN24-1363 ASYMPTOMATIC HYPONATREMIA AND ASSOCIATION WITH PERITONITIS IN PERITONEAL DIALYSIS
by: Francesco Zurita Parodi, et al.
Published: (2024-04-01)

WCN24-1672 “TESTOSTERONE DEFICIT IN DIALYSIS: EVALUATION, IMPACT AND ASSOCIATION WITH COMORBILITY MARKERS AND TIME ON DIALYSIS.”
by: Damian Bombicino, et al.
Published: (2024-04-01)

WCN24-665 Influence of Dialysis Clinical Operational Conditions on
by: Amira Abdelrasoul, et al.
Published: (2024-04-01)

WCN24-1025 Hemophilia: the last stronghold of hypocogulation in dialysis
by: Sofia Sousa, et al.
Published: (2024-04-01)

WCN24-244 The utility of Indoxyl sulfate as a biomarker for early detection of CKD
by: Mizuki Hisano, et al.
Published: (2024-04-01)

WCN24-2070 Calprotectin Is Associated with Vascular Calcification and Cardiovascular Complications During CKD
by: Serban Ardeleanu, et al.
Published: (2024-04-01)

WCN24-1377 HYPOKALEMIA AS A RISK FACTOR FOR PERITONITIS IN PERITONEAL DIALYSIS
by: Francesco Zurita Parodi, et al.
Published: (2024-04-01)